ArticleCureus2025
Progressive Anterior Tibial Tumefaction: A Case of Unusual Bone Lesion.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Brown tumors are rare, non-neoplastic bone lesions caused by excessive bone remodeling due to hyperparathyroidism. Their estimated prevalence is approximately 3-5% in primary hyperparathyroidism and about 1.5% in secondary forms. Prolonged elevation of parathyroid hormone (PTH) stimulates osteoclastic activity, leading to progressive bone resorption and cortical disruption. These lesions develop through replacement of normal bone marrow by highly vascularized fibrous tissue, often accompanied by repeated microfractures and hemorrhage, resulting in pain, skeletal deformity, structural weakness, and an increased risk of fractures. Their clinical and radiologic resemblance to malignancy often poses a diagnostic challenge. We report the case of an 81-year-old male who presented with a progressively enlarging, painless tumefaction on the anterior aspect of the right tibia. Magnetic resonance imaging (MRI) of the lower limb revealed a large heterogeneous lesion with internal cystic areas, initially suggestive of a secondary bone process. Laboratory studies showed markedly elevated parathyroid hormone (PTH 705 pg/dL), hypercalcemia (11.5 mg/dL), increased alkaline phosphatase (ALP 416 U/L), and elevated prostate-specific antigen (PSA 11.88 ng/mL). Bone scintigraphy demonstrated diffuse uptake compatible with metabolic bone disease. Thoracoabdominal-pelvic computed tomography (TAP-CT) showed diffuse bone involvement, raising suspicion of metastatic disease, and a heterogeneous thyroid gland with small nodules in the right lobe. The possibility of primary thyroid neoplasia was ruled out after thyroid ultrasound and biopsy of the thyroid nodule were performed. Due to the elevated PSA, a PSMA-PET (prostate-specific membrane antigen positron emission tomography) was requested, which demonstrated diffuse bone involvement not compatible with metastasis from a primary prostate neoplasm. The free-to-total PSA ratio and digital rectal examination were consistent with benign prostatic hyperplasia. Due to elevated PTH and calcium levels, parathyroid scintigraphy was requested, which revealed a hyperfunctioning parathyroid nodule, compatible with a parathyroid adenoma. Biopsy of the tibial lesion confirmed a brown tumor, likely secondary to primary hyperparathyroidism caused by a parathyroid adenoma. The patient underwent a successful parathyroidectomy. Although rare, brown tumors should be considered in the differential diagnosis of osteolytic bone lesions, especially in the presence of elevated PTH. Recognition of this entity is essential to prevent misdiagnosis and unnecessary oncologic treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.